Transitioning to WHODrug Global?

Are you a user of WHODrug Enhanced? Please view our recommendations and download our WHODrug Global Transition plan below for more practical information regarding your transition.

UMC recommends the following:

For new studies, starting after 15 March 2019, the use of WHODrug Global is required by U.S. FDA.

For ongoing studies that are regularly upversioned and are planned to end before 2020, the sponsor and CRO should decide together whether to upgrade to WHODrug Global or not.

Ongoing studies that are regularly upversioned and are planned to end after 2020, should be upgraded to WHODrug Global when convenient.

It is acceptable for studies that are not upgraded to stay on the initial version, but we recommend ensuring that it complies with regulatory expectations.

Documents

Read more about WHODrug

Last modified on: July 31, 2019
.